PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease. 1977

J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer

14 untreated patients with Hodgkin's disease were tested for lymphocte reactivity in vitro to optimal and suboptimal doses of PHA. A PHA dose-dependent defect in lymphocyte stimulation was demonstrated in patients when compared with a group of normal individuals. No correlation between the in vitro defect and decreased absolute number of E-rosette-forming cells (T-lymphocytes) in peripheral blood was found.

UI MeSH Term Description Entries
D007158 Immunologic Techniques Techniques used to demonstrate or measure an immune response, and to identify or measure antigens using antibodies. Antibody Dissociation,Immunologic Technic,Immunologic Technics,Immunologic Technique,Immunological Technics,Immunological Techniques,Technic, Immunologic,Technics, Immunologic,Technique, Immunologic,Techniques, Immunologic,Antibody Dissociations,Dissociation, Antibody,Dissociations, Antibody,Immunological Technic,Immunological Technique,Technic, Immunological,Technics, Immunological,Technique, Immunological,Techniques, Immunological
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D005260 Female Females
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer
December 1977, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer
January 1978, Nihon rinsho. Japanese journal of clinical medicine,
J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer
January 1979, Rivista di emoterapia ed immunoematologia,
J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer
May 1978, Acta neurologica Scandinavica,
J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer
October 1973, The New England journal of medicine,
J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer
January 1979, Journal of immunopharmacology,
J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer
January 1990, Cancer immunology, immunotherapy : CII,
J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer
April 1976, The New England journal of medicine,
J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer
May 1978, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
J M Land, and J Litwin, and P Bigel, and F Oberling, and S Mayer
January 1973, Haematologica,
Copied contents to your clipboard!